Background
CCAAT/Enhancer Binding Proteinδ (C/EBPδ) is a member of the highly conserved C/EBP family of leucine zipper DNA binding proteins [
1‐
3]. C/EBPδ gene expression is increased in nontransformed mammary epithelial cells (MECs) in response to G
0 growth arrest conditions and IL-6 family cytokine treatment [
4‐
11]. Ectopic C/EBPδ expression induces growth arrest of mammary epithelial, prostate and chronic myelogenous leukemia cell lines [
5,
12,
13]. Conversely, reducing C/EBPδ gene expression is associated with delayed growth arrest, genomic instability, impaired contact inhibition, increased cell migration and increased growth in reduced serum media [
5,
14].
In vivo, female C/EBPδ knockout mice exhibit increased mammary epithelial cell proliferation and mammary gland ductal hyperplasia [
15].
"Loss of function" alterations in C/EBPδ gene expression have been reported in human and experimental cancer. Using Serial Analysis of Gene Expression (SAGE) assays Polyak and coworkers demonstrated that C/EBPδ is down regulated in the progression from normal breast epithelium to advanced breast cancer [
16,
17]. Other reports have shown that C/EBPδ gene expression is reduced in ~30% of primary human breast tumors and in primary prostate tumors [
11,
18]. In experimental models, C/EBPδ expression is reduced in carcinogen-induced mammary tumors and in ~50% of mammary tumors isolated from MMTV/c-neu transgenic mice [
19,
20].
Studies addressing the mechanisms underlying loss of function alterations in C/EBP gene expression demonstrated that the C/EBPδ gene promoter is silenced by promoter hypermethylation in the SUM-52PE human breast cancer cell line (26/27 CpGs methylated) and by site-specific methylation in primary human breast tumor isolates [
11]. C/EBPδ gene expression is also silenced by promoter hypermethylation in primary cervical cancer and hepatocellular carcinoma (HCC) [
21]. In addition to solid tumors, C/EBPδ gene expression is reduced and the C/EBPδ promoter is silenced by hypermethylation in the U937 human lymphoma derived cell line and in ~35% of lymphoma cells isolated from AML patients [
22]. Although C/EBPδ expression is reduced in primary tumors and cancer derived cell lines inactivating mutations in the intronless C/EBPδ gene are rare [
23,
24]. This indicates that alterations in regulatory mechanisms that control C/EBPδ gene expression play a key role in cancer-related C/EBPδ "loss of function" alterations. We used nuclear run-on assays to investigate C/EBPδ transcriptional regulation and found that C/EBPδ gene transcription is induced ~6 fold in G
0 growth arrested nontransformed mammary epithelial cells compared to actively proliferating mammary epithelial cells [
6]. These findings demonstrated the importance of transcriptional control of C/EBPδ gene expression and suggested that alterations in transcriptional activators or repressors would have a major impact on C/EBPδ expression and cellular growth control.
c-Myc (Myc) is a member of the Myc family of helix loop helix proteins that function in the activation and repression of target gene transcription [
25]. Myc expression promotes cell proliferation and Myc over expression has been documented in a wide range of human cancers [
25]. The Myc gene is frequently amplified in breast cancer and experimental studies indicate that Myc is a downstream transcriptional effector of ErbB2 receptor tyrosine kinase activation, a signaling pathway that is commonly dysregulated and constitutively active in breast cancer [
26,
27]. Accumulating evidence indicates that transcriptional repression of Myc target genes is a major mechanism in which Myc promotes cell transformation [
28]. Myc represses the transcription of key growth control, differentiation and tumor suppressor genes including GAS1, p15
INK 4, p21
CIP 1, p27
KIP 1, p57
KIP 2, growth arrest and DNA damage 34 (GADD34), GADD45, C/EBPα and GADD153 (C/EBPζ) [
25,
28‐
42].
We previously reported that the C/EBPδ proximal promoter is in a constitutively "open" chromatin conformation and that the C/EBPδ proximal promoter is accessible to activating (Sp1, pSTAT3, CREB) and repressive (Myc) transcriptional regulatory factors [
43]. Myc repression of C/EBPδ gene transcription may promote mammary tumorigenesis as C/EBPδ functions as a transcriptional activator of growth arrest, differentiation, apoptosis and inflammation related genes [
3,
44]. Myc repression is mediated by Myc interactions with promoter-bound transcriptional control proteins such as Sp1, Smads and Miz1 [
25,
44]. In this report, we provide new mechanistic insights into Myc repression of C/EBPδ gene expression. We demonstrate that Myc repression of the C/EBPδ promoter is dependent on Myc Box II (MBII), basic region (BR), helix-loop-helix (HLH) region and the leucine zipper (LZ) domains. In addition, we demonstrate that Myc repression of the C/EBPδ promoter is dependent on Miz1 and Max; two Myc interacting proteins that are constitutively associated with the C/EBPδ proximal promoter. Miz1 is required for Myc repression of C/EBPδ promoter activity but Miz1 does not activate the C/EBPδ promoter in nontransformed mammary epithelial cells. These results indicate that Miz1 functions exclusively in Myc mediated repression of C/EBPδ in nontransformed mammary epithelial cells. In addition, endogenous C/EBPδ expression is increased in cells treated with Miz1 and Max siRNAs, supporting a role for both Max and Miz1 in Myc repression of C/EBPδ expression. Finally, RuvBl1 (Pontin, TIP49) and RuvBl2 (Reptin, TIP48), two AAA+ family DNA helicases that interact with Myc Box II, repress C/EBPδ promoter activity [
45]. These results provide new insights into Myc protein-protein interactions and the functional roles of Miz1, Max, RuvBl1 and RuvBl2 in Myc repression of C/EBPδ expression.
Discussion
The findings from this study demonstrate that Myc represses C/EBPδ expression by associating with the C/EBPδ proximal promoter as transient component of a multi-protein repressive complex. Transcriptional repression is a major mechanism of Myc oncogenesis and Myc repressed genes include critical regulators of cell cycle progression, growth arrest and differentiation such as p21
CIP 1, p27
KIP 1, p15
INK 4, p18
INK 4c, p57
KIP 2, gas1, and C/EBPα [
44]. Myc repression of C/EBPδ transcription is Miz1 dependent, indicating that Myc repression of C/EBPδ transcription parallels Myc repression of p15
INK
, p21
CIP 1, p27
KIP 1, Mad4 and C/EBPα [
25]. However, Miz1 does not function as a transcriptional activator of the C/EBPδ promoter in nontransformed mammary epithelial cells, differentiating Miz1 function in the regulation of C/EBPδ from p15
INK
, p21
CIP 1and Mad4 [
44]. Although Miz1 does not activate the C/EBPδ promoter, ChIP assays demonstrated that Miz1 is constitutively associated with the C/EBPδ promoter. EMSA analysis localized the Miz1 binding site to the -100 to -70 region of the C/EBPδ proximal promoter. This a region contains a candidate Inr (-85 to -93) immediately downstream of STAT3/Sp1 consensus sites (-120 to -104) that are associated with C/EBPδ transcriptional activation [
7,
54]. We and others have reported that pSTAT3 is a potent transcriptional activator of C/EBPδ gene expression [
7,
8]. The presence of the Miz1 binding site downstream of the C/EBPδ consensus transcriptional activation sites provides a rationale for how Myc represses C/EBPδ expression in actively cycling cells that exhibit increased pSTAT3 in response to IL-6 family cytokines [
43]. These findings suggest that Myc repression of C/EBPδ expression could contribute to the cascade of Myc mediated events that result in aberrant cell proliferation and enhanced transformation.
Max, a well-established Myc binding partner, also plays a key role in Myc repression of C/EBPδ expression. Like Miz1, Max is constitutively associated with the C/EBPδ promoter even in the absence of Myc, a finding that is consistent with a previous report by Mao, et al, [
52]. The recruitment of Miz1 and Max to the C/EBPδ proximal promoter may be facilitated by the C/EBPδ proximal promoter "open" chromatin conformation [
43]. We previously reported that the C/EBPδ proximal promoter is in an open chromatin conformation and "pre-loaded" with transcriptional machinery components associated with transcriptional activation including Sp1, cyclic AMP response element-binding protein (CREB), TATAA Binding protein (TBP) and RNA Pol II [
43]. The present results demonstrate that Miz1 and Max, two proteins that function in C/EBPδ transcriptional repression, are also constitutively associated with the C/EBPδ promoter. These results are consistent with a model in which the C/EBPδ proximal promoter exists in a unique state, poised for activation or repression by the constitutive presence of proteins that mediate both transcriptional activation and repression.
Although Myc transcriptional repression is critical for Myc mediated cell transformation, the proteins that interact with Myc and function in gene repression are poorly characterized. RuvBl1 (Pontin, TIP49) and RuvBl2 (Reptin, TIP48) are two AAA+ ATPase helicases that interact with Myc Box II and function in Myc transcriptional repression, and have been shown to increase cell proliferation and transformation [
55‐
57]. Individually, both RuvBl1 and RuvBl2 repressed C/EBPδ promoter activity, however, co-expression of RuvBl1 and RuvBl2 was most effective in repressing C/EBPδ promoter activity. This suggests that Myc transcriptional repression of C/EBPδ may be mediated by a multi-protein complex composed of DNA bound Miz1, Myc/Max and possibly RuvBl1 and RuvBl2. Studies in
Xenopus demonstrated that RUVBL1/RUVBL2 (xPontin/xReptin) induce cell proliferation during embryogenesis by enhancing Myc repression of p21 [
58]. Our findings suggest that a similar mechanism may mediate Myc repression of C/EBPδ and possibly other growth suppressor genes (such as p21
Waf 1/CIP 1), in promoting aberrant mammary epithelial cell proliferation and transformation.
Despite the critical role of Myc transcriptional repression in cell transformation, the mechanism by which Myc transcriptional repression leads to cell transformation is poorly understood. Several lines of evidence indicate that Myc can recruit DNA methyltransferases and that Myc transcriptional repression can progress to transcriptional silencing. For example, Myc repression of p21
Waf 1/CIP1transcription in human U2OS osteosarcoma cells occurs via formation of a repressive complex including Myc, Miz1 and DNA Methyltransferase3a (Dnmt3a) [
59]. In addition, studies in human cervical and hepatocellular carcinoma cells have shown recruitment of DNA methyltransferases and silencing of the human C/EBPδ (CEBPD) promoter by hypermethylation [
21]. Our lab reported that the C/EBPδ gene is silenced by promoter hypermethylation in the SUM-52PE human breast cancer cell line and that primary breast tumors exhibiting reduced C/EBPδ expression are characterized by site-specific promoter methylation [
10,
11,
54]. The results from this study demonstrate that Myc repression of C/EBPδ transcription is a regulated process that is coordinated with cell cycle status in nontransformed cells. Further studies are needed to determine how this regulated Myc repression function is altered and progresses to gene silencing and cell transformation.
Conclusion
The results of this study identify protein-protein and DNA-protein interactions that mediate Myc repression of C/EBPδ gene expression. These results extend current working models of Myc transcriptional repression and suggest future directions to pursue in the characterization of the network of proteins that function in Myc transcriptional repression. The results presented have focused on Myc repression of the mouse C/EBPδ promoter in HC11 mouse nontransformed mammary epithelial cells; however, human Myc expression constructs also repress the human C/EBPδ promoter in nontransformed human mammary epithelial cells (MCF-10A) (data not shown). Current experiments are focused on further characterizing Myc interacting proteins, deciphering the sequence of events that mediate Myc repression of C/EBPδ in nontransformed mouse and human cells, and determining how this sequence progresses to gene silencing and cell transformation. Defining the protein interactions that mediate Myc repression, and the role of Myc in the silencing of tumor suppressor genes, will facilitate the development of pharmacological interventions to inhibit the functions of Myc that promote cell transformation.
Methods
Cell Culture
HC11 mouse mammary epithelial cells were grown in complete growth media (CGM) containing RPMI 1640 medium plus 5% fetal bovine serum (FBS), 10 μg/ml bovine insulin, 10 ng/ml epidermal growth factor, 100 U/ml penicillin, 100 μg/ml streptomycin and 500 ng/ml Fungizone. Growth arrest was induced by 24~48 hrs serum and growth factor withdrawal (growth arrest medium, GAM, 0.1% FBS).
Plasmid Constructs
Mouse C/EBPδ proximal promoter sequence flanking -127 bp to transcriptional start site (P-127, containing Sp1, STAT3 and CREB binding sites) was constructed in the pGL2 basic luciferase reporter vector [
7,
60]. Myc and MycV394D mutant constructs in pBabe-puro vector were a generous gift from Dr. Martin Eilers (Institute for Molecular Biology and Tumor Research, University of Marburg, Germany). Myc and MycV394D were then amplified by PCR from pBabe-puro vector using primers specific for Myc. The primer sequences for Myc wild type and MycV394D cloning are as follows: 5'-CGCGGATCCGCGATGCCCCTCAACGTTAGCTTC-3' (forward primer) and 5'-GCTCTAGACGCGCACAAGAGTTCCGTAGCTG-3' (reverse primer). Myc deletion constructs MycΔ45-63(MB1), MycΔ129-143(MB2), MycΔ355-367(BR), MycΔ368-410(HLH) and MycΔ411-439(LZ) were constructed by site-specific mutagenesis as previously described [
61,
62]. Myc-, Myc deletion- and V394D- pcDNA3.1-V5-His expression constructs were verified by sequencing. The Miz1 full length cDNA construct in pCMV6 vector was purchased from Origene.
Transfection Protocol
HC11 cells were plated in 12-well plates, grown to 50% confluence in CGM and transfected using the enhanced Lipofectamine transfection protocol (Invitrogen, Carlsbad, CA) as previously described [
60]. Co-transfections were performed with 0.3 ug C/EBPδ promoter luciferase reporter construct, 1 ng Renilla luciferase reporter construct (transfection efficiency control), and 5~50 ng of expression constructs or vector controls. For growth arrest experiments, transfected cells were washed 2× with PBS and cultured in GAM for 24-48 hours. Cells were harvested and assayed for firefly and renilla luciferase activities using the Dual-Luciferase Reporter Assay kit with luciferase detection by Hewlett-Packard Lumicount microplate luminometer as previously described [
43]. C/EBPδ promoter activities were normalized to renilla luciferase activity. Results shown are the average-fold changes from 3 independent experiments with duplicates. Co-immunoprecipitation experiments were performed as described [
43,
61,
62]. HC11 cell lysates used in co-immunoprecipitation assays were prepared by transfecting Myc or V394D Myc mutant expression constructs (1 μg) (Lipofectamine) into HC11 cells. HC11 Miz1 and Max siRNA transfections were performed using the Amaxa Nucleofector (Amaxa, Inc., Cologne, Germany). Briefly, HC11 cells were suspended in Amaxa Nucleofector Solution V supplemented with 50 pmol Miz1 or Max Smartpool siRNAs (Dharmacon, Inc., Lafayette, CO) and the nucleofection was performed using cell-type specific protocol (T-20). HC11 cells nucleofected with non-specific scrambled siRNAs were used as controls. Transient siRNA nucleofection protocols were optimized and protocols achieving >80% specific gene knockdown as verified by western blot were used in all experiments.
Western blot and co-immunoprecipitation assays
Western blots were performed on whole cell lysates as previously described [
61,
62]. Co-immunoprecipitation assays were performed with HC11 cell lysates isolated by NP-40 lysis, primary antibody immunoprecipitation, Protein A-Agarose bead pull down, elution and analysis by SDS PAGE as previously described [
61]. Co-immunoprecipitations were performed 2-3 times and representative results presented.
Chromatin immunoprecipitation (ChIP)
ChIP experiments were performed using the Chromatin Immunoprecipitation (ChIP) Assay Kit (Sigma) as previously described [
3,
43]. Briefly, HC11 cells were cross-linked with 1% formaldehyde, washed 3× with cold PBS (4°C), and the nuclear pellets were collected by centrifuge. Nuclear pellets were then resuspended in 300 μl DNA shearing buffer containing protease inhibitor cocktail, sonicated on ice to approximately 200~1000 bp (verified by standard agarose gel analysis), centrifuged at 14000 rpm for 10 minutes to pellet cell debris and the supernatants were collected and diluted 1:1 in dilution buffer and used for DNA immunoprecipitation. 10 ul diluted supernatant was used as input control. One μg of Myc or Miz1 specific IgG immunoprecipitated protein-DNA complexes were isolated and protein-DNA crosslinks reversed (65°C, 2 hours). After purification, immunoprecipitated DNA was analyzed by PCR using primers specific for proximal and distal mouse C/EBPδ promoter [
60]. Primer sequences are as follows: P200 (region -226 to -24 of the mouse C/EBPδ promoter containing STAT3 and SP1 binding sites), 5'-GCGTGTCGGGGCCAAATCCA-3'(forward primer), 5'-TTTCTAGCCCCAGCTGACGCGC-3'(reverse primer); P1.8K (region -1856 to -1676 of the promoter) as control, 5'-TGCTTCTATGGCATCCAG-3'(forward primer), 5'-GAGGGGCTGTGGAATATT-3'(reverse primer).
Miz1 protein purification
Full length Miz1 cDNA was cloned into pGEX-4T-1 vector (Miz1-GST). The Miz1-GST plasmid was transformed to BL21 (DE3) competent cell (Stratagene). The Miz1-GST protein was purified by affinity binding using Glutathione sepharose beads (GE Healthcare) following the manufacturer's protocol. Miz1 protein was confirmed by western blot with detection using Miz1 and GST antibodies (Santa Cruz, Biotechnology).
Electromobility Shift Assay (EMSA)
DNA probes (a to g) were generated by PCR using mouse C/EBPδ promoter (1.7 kb fragment) as template. Primer sequences are available upon request. Double stranded oligos used to produce Probes h, j, and i were purchased (Sigma). Probes used in EMSA reactions were 5' end-labeled with 6-FAM (6-Carboxyfluorescein, Sigma). EMSAs were performed by incubating labeled probes (20 ng) with purified Miz1 protein in binding buffer (10 mM Tris pH 7.9, 4 mM MgCl2, 5% glycerol, 0.1 mM DTT, 20 ng/μl poly(dI:dC) and 0.2% NP-40) for one hour at room temperature. To perform EMSA competition assays unlabelled probes were pre-incubated with Miz1 in binding buffer for 10 min prior to addition of the labeled probe. The concentration of unlabeled probes used was 5-25-fold molar excess over labeled probe. Following incubation, samples were loaded onto a 4.5% native acrylamide gel (pre-run for one hour) and electrophoresed for one hour at 100 V. Gels were scanned using the Typhoon 9410 imager (GE healthcare).
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
All authors contributed to the experimental design, data interpretation, and manuscript development. JS, XY and YZ carried out the experiments, initial data analysis and figure design and optimization. JD advised on all experimental design aspects, data interpretation and final manuscript form. All authors have read and approve of the contents of this manuscript.